CO4950604A1 - Azetidinas - Google Patents
AzetidinasInfo
- Publication number
- CO4950604A1 CO4950604A1 CO98037815A CO98037815A CO4950604A1 CO 4950604 A1 CO4950604 A1 CO 4950604A1 CO 98037815 A CO98037815 A CO 98037815A CO 98037815 A CO98037815 A CO 98037815A CO 4950604 A1 CO4950604 A1 CO 4950604A1
- Authority
- CO
- Colombia
- Prior art keywords
- optionally substituted
- halogens
- aryl
- alkyl optionally
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de fórmula (I):y sus sales farmacéuticamente aceptables, en la queA es CO, SO2 o CH2 ; Ar1 es fenilo opcionalmente sustituido por uno o más sustituyentes seleccionadosindependientemente de halógeno, alcoxilo C1-6 opcionalmente sustituido por uno o más halógenos, y alquilo C1-6 opcionalmente sustituido por uno o más halógenos; X1 es cicloalquilo C3-7 , arilo o alquilo C1-6 , estando dicho alquilo C1-6 opcionalmente sustituido por flúor, CO2 H, CO2 (alquilo C1-4 ), cicloalquilo C3-7 , adamantilo, arilo o het,y estando dicho cicloalquilo C3-7 sustituido opcionalmente por uno o dos sustituyentes seleccionados cada uno de ellos independientemente de alquilo C1-4 , cicloalquilo C3-7 , alcoxilo C1-4 , OH, F, fluoro(alquilo C1-4 ) y fluoro(alcoxilo C1-4 ).X es un enlace directo o NR1 ; R es SO2 arilo, SO2 (alquilo C1-6 opcionalmente sustituido por uno o más halógenos), R1 es H, alquilo C1-6 opcionalmente sustituido por uno o más halógenos, o R1 es fenilo opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente de halógeno, alcoxilo C1-6 opcionalmente sustituido por uno o más halógenos, o alquilo C1-6 opcionalmente sustituido por uno o más halógenos; Y es O, NCO(alquilo C1-6 opcionalmente sustituido por uno o más halógenos), NCO2 (alquilo C1-6 opcionalmente sustituido por uno o más halógenos), NSO2 (alquilo C1-6 opcionalmente sustituido por uno o más halógenos), NCOarilo, NCO2 arilo, NSO2 arilo, NSO2 (alquilo C1-6 opcionalmente sustituido por uno o más halógenos), CH2 , CHF, CF2 , NH, NCH2 arilo, N(alquilo C1-6 opcionalmente sustituido por uno o más halógenos), o NCH2 (cicloalquilo C3-7 );con la condición de que X no sea NR1 cuando R esen el que la expresión "arilo" utilizada en todas las definiciones anteriores representa fenilo o naftilo opcionalmente sustituido con uno o más sustituyentes, independientemente seleccionados de halógeno, alcoxilo C1-6 opcionalmente sustituido por uno o más halógenos, alquilo C1-6 opcionalmente sustituido por uno o más halógenos;y la expresión "het" utilizado en la definición de X1 significa tienilo o un grupo heteroarilo cíclico de 5 ó 6 eslabones que contiene bien 1 ó 2 heteroátomos de nitrógeno, o bien 1 heteroátomo de nitrógeno y 1 heteroátomo de oxígeno o azufre, cada uno sustituido opcionalmente por 1 ó 2 sustituyentes cada uno seleccionado independientemente de alquilo C1-4 , alcoxilo C1-4 , halógeno, flúor(alquilo C1-4 ) yflúor(alcoxilo C1-4 ).Un compuesto o sal conforme a la reivindicación 1 en el que A es CO o SO2 .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9714129.5A GB9714129D0 (en) | 1997-07-04 | 1997-07-04 | Azetidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4950604A1 true CO4950604A1 (es) | 2000-09-01 |
Family
ID=10815370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98037815A CO4950604A1 (es) | 1997-07-04 | 1998-07-03 | Azetidinas |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6262046B1 (es) |
| EP (1) | EP1023285A1 (es) |
| JP (1) | JP2000511207A (es) |
| KR (1) | KR20010015532A (es) |
| CN (1) | CN1261887A (es) |
| AP (1) | AP1110A (es) |
| AR (1) | AR013171A1 (es) |
| AU (1) | AU726708B2 (es) |
| BG (1) | BG103992A (es) |
| BR (1) | BR9810544A (es) |
| CA (1) | CA2294193A1 (es) |
| CO (1) | CO4950604A1 (es) |
| DZ (1) | DZ2550A1 (es) |
| EA (1) | EA002773B1 (es) |
| GB (1) | GB9714129D0 (es) |
| GT (1) | GT199800106A (es) |
| HN (1) | HN1998003689A (es) |
| HR (1) | HRP20000002B1 (es) |
| HU (1) | HUP0002330A3 (es) |
| ID (1) | ID24090A (es) |
| IL (1) | IL133433A0 (es) |
| IS (1) | IS5295A (es) |
| MA (1) | MA26519A1 (es) |
| NO (1) | NO996115L (es) |
| NZ (1) | NZ501715A (es) |
| OA (1) | OA11236A (es) |
| PA (1) | PA8454601A1 (es) |
| PE (1) | PE83999A1 (es) |
| PL (1) | PL338004A1 (es) |
| SK (1) | SK182799A3 (es) |
| TN (1) | TNSN98127A1 (es) |
| TR (1) | TR200000025T2 (es) |
| TW (1) | TW492960B (es) |
| UY (1) | UY25079A1 (es) |
| WO (1) | WO1999001451A1 (es) |
| ZA (1) | ZA985875B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714129D0 (en) | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
| AU1089599A (en) * | 1997-10-15 | 1999-05-03 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| FR2787449B3 (fr) * | 1998-12-15 | 2001-01-12 | Sanofi Sa | Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation |
| FR2787448B3 (fr) | 1998-12-18 | 2001-01-12 | Sanofi Sa | Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| ES2282731T3 (es) * | 2002-12-23 | 2007-10-16 | Janssen Pharmaceutica N.V. | Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas. |
| TW200508221A (en) | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
| FR2876689B1 (fr) * | 2004-10-14 | 2008-02-22 | Aventis Pharma Sa | Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| EA014239B1 (ru) * | 2005-03-08 | 2010-10-29 | Янссен Фармацевтика Н.В. | Производные диаза-спиро-[4,4]нонана в качестве антагонистов нейрокинина (nk1) |
| US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| TW200812963A (en) * | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| US8106208B2 (en) | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| CA2676357A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| RU2010106974A (ru) * | 2007-08-07 | 2011-09-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3 |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | 抗がん剤 |
| EP3315499B1 (en) | 2015-06-23 | 2021-04-07 | Eisai R&D Management Co., Ltd. | Crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676055B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5625060A (en) | 1991-05-03 | 1997-04-29 | Elf Sanofi | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present |
| TW432061B (en) * | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
| FR2729951B1 (fr) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
| GB9600235D0 (en) | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
| GB9601697D0 (en) | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
| GB9714129D0 (en) | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
-
1997
- 1997-07-04 GB GBGB9714129.5A patent/GB9714129D0/en active Pending
-
1998
- 1998-06-01 TW TW087108533A patent/TW492960B/zh active
- 1998-06-30 HN HN1998003689A patent/HN1998003689A/es unknown
- 1998-07-01 MA MA25151A patent/MA26519A1/fr unknown
- 1998-07-01 DZ DZ980160A patent/DZ2550A1/xx active
- 1998-07-01 SK SK1827-99A patent/SK182799A3/sk unknown
- 1998-07-01 UY UY25079A patent/UY25079A1/es not_active IP Right Cessation
- 1998-07-01 EA EA199901102A patent/EA002773B1/ru not_active IP Right Cessation
- 1998-07-01 TR TR2000/00025T patent/TR200000025T2/xx unknown
- 1998-07-01 PL PL98338004A patent/PL338004A1/xx unknown
- 1998-07-01 WO PCT/EP1998/004177 patent/WO1999001451A1/en not_active Ceased
- 1998-07-01 CA CA002294193A patent/CA2294193A1/en not_active Abandoned
- 1998-07-01 KR KR1020007000013A patent/KR20010015532A/ko not_active Abandoned
- 1998-07-01 HU HU0002330A patent/HUP0002330A3/hu unknown
- 1998-07-01 JP JP11506382A patent/JP2000511207A/ja active Pending
- 1998-07-01 EP EP98939619A patent/EP1023285A1/en not_active Withdrawn
- 1998-07-01 NZ NZ501715A patent/NZ501715A/en unknown
- 1998-07-01 PE PE1998000589A patent/PE83999A1/es not_active Application Discontinuation
- 1998-07-01 CN CN98806898A patent/CN1261887A/zh active Pending
- 1998-07-01 BR BR9810544-2A patent/BR9810544A/pt not_active IP Right Cessation
- 1998-07-01 ID IDW20000006A patent/ID24090A/id unknown
- 1998-07-01 AU AU88062/98A patent/AU726708B2/en not_active Ceased
- 1998-07-01 IL IL13343398A patent/IL133433A0/xx unknown
- 1998-07-01 HR HR970497A patent/HRP20000002B1/xx not_active IP Right Cessation
- 1998-07-01 US US09/423,771 patent/US6262046B1/en not_active Expired - Fee Related
- 1998-07-02 PA PA19988454601A patent/PA8454601A1/es unknown
- 1998-07-02 AP APAP/P/1998/001291A patent/AP1110A/en active
- 1998-07-02 AR ARP980103228A patent/AR013171A1/es not_active Application Discontinuation
- 1998-07-03 CO CO98037815A patent/CO4950604A1/es unknown
- 1998-07-03 ZA ZA9805875A patent/ZA985875B/xx unknown
- 1998-07-10 TN TNTNSN98127A patent/TNSN98127A1/fr unknown
- 1998-07-14 GT GT199800106A patent/GT199800106A/es unknown
-
1999
- 1999-12-10 NO NO996115A patent/NO996115L/no not_active Application Discontinuation
- 1999-12-10 IS IS5295A patent/IS5295A/is unknown
- 1999-12-13 BG BG103992A patent/BG103992A/xx unknown
- 1999-12-15 OA OA9900282A patent/OA11236A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4950604A1 (es) | Azetidinas | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| BRPI0506817A (pt) | inibidores seletivos de quinase | |
| BRPI9908319B8 (pt) | composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo. | |
| DE69232883D1 (de) | Substituierte heterocyklische derivate, verwendbar als plättchenaggregationshemmstoffe | |
| ES2163417T3 (es) | Derivados de benzamida. | |
| ES2062706T3 (es) | Nuevos derivados de amino-metil-piperidina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ATE325788T1 (de) | Kristalle von vitamin d derivaten und verfahren zu ihrer herstellung | |
| CO4950607A1 (es) | Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg c o a reductasa para el tratamiento del cancer | |
| ES2026666T3 (es) | Procedimiento para preparar derivados de imidazopiridinas. | |
| ATE119532T1 (de) | 7-oxabicycloheptyl-substituierte, heterocyclische amid-prostaglandin-analoge, verwendbar bei der behandlung von vasospastischen und thrombotischen krankheiten. | |
| EA200101204A1 (ru) | Новые бициклические соединения аминопиразинона, способ их получения и содержащие их фармацевтические композиции | |
| DK185984D0 (da) | Disubstituerede polymethyleniminer,fremgangsmaader til deres fremstilling og farmaceutiske kompositioner indeholdende dem | |
| DK330588A (da) | Tripeptidderivater med en polycyklisk nitrogenholdig struktur, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem | |
| ES2159693T3 (es) | Ligandos 5ht1dalfa y 5ht2a. | |
| AR248276A1 (es) | Derivados de imidazolidina, procedimiento para producirlos y pesticidas que los contienen | |
| AR038443A1 (es) | Derivados de aminoacidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ATE84303T1 (de) | Cysteinderivate. | |
| YU48094B (sh) | Derivati fenoksietilamina i postupak za njihovo dobijanje | |
| DK63183D0 (da) | Fremgangsmade til fremstilling af guanidino-heterocycliske phenylamidiner og syreadditionssalte deraf | |
| CO5650254A2 (es) | Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa | |
| SV2001000050A (es) | Compuestos farmaceuticos caso n.g.1336 | |
| CO4750648A1 (es) | 5-naftalen-1-il-1,3 dioxanos, su preparacion y composiciones farmaceuticas que los contienen | |
| IS7911A (is) | Ímídasólafleiður með sækni í alfa 2 viðtakavirkni | |
| ES2154561B1 (es) | Derivados de 2-fenilpiran-4-ona. |